Assessment of the protective effect of imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques

Journal of Virology

Volumn 87, Issue 14, 2013, Pages 7805-7815

  Hatch, Graham J ^a   Graham, Victoria A ^a   Bewley, Kevin R ^a   Tree, Julia A ^a   Dennis, Mike ^a   Taylor, Irene ^a   Funnell, Simon G P ^a   Bate, Simon R ^a   Steeds, Kimberley ^a   Tipton, Thomas ^a   Bean, Thomas ^a   Hudson, Laura ^a   Atkinson, Deborah J ^a   McLuckie, Gemma ^a   Charlwood, Melanie ^a   Roberts, Allen D G ^a   Vipond, Julia ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; VIRUS ANTIBODY;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYNOMOLGUS MACAQUE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOPHENOTYPING; INFECTION PREVENTION; MACACA; MALE; MONKEYPOX; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROAT CULTURE; VACCINATION; VIRUS EXCRETION; VIRUS LOAD;

ANIMALS; ANTIBODIES, NEUTRALIZING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNIZATION; MACACA FASCICULARIS; MALE; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; SMALLPOX VACCINE; VACCINES, ATTENUATED; VIRUS SHEDDING;

EID: 84880301278     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03481-12     Document Type: Article

References (46)

1. Chapman JL, Nichols DK, Martinez MJ, Raymond JW. 2010. Animal models of orthopoxvirus infection. Vet. Pathol. 47:852-870.
2. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA, Wong SAS, Huynh T, Baskin CR. 2009. Vaccinia virus vaccines: past, present, and future. Antivir. Res. 84:1-13.
3. World Health Organization. 2001. Smallpox. Wkly. Epidemiol. Rec. 76: 337-344.
4. von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, Handley A, Mateo L, Siersbol H, Kollaritsch H, Chaplin P. 2010. A randomized, double-blind, dose-finding phase II study to evaluate immunogenicity and safety of the third-generation smallpox vaccine candidate Imvamune. Vaccine 28:1209-1216.
5. Bhanuprakash V, Venkatesan G, Balamurugan V, Hosamani M, Yogisharadhya R, Gandhale P, Reddy KV, Damle AS, Kher HN, Chandel BS, Chauhan HC, Singh RK. 2010. Zoonotic infections of buffalopox in India. Zoonoses Public Health 57:e149-155.
6. Glatz M, Richter S, Ginter-Hanselmayer G, Aberer W, Mullegger RR. 2010. Human cowpox in a veterinary student. Lancet Infect. Dis. 10:288.
7. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham BS, Formenty P, Okitolonda E, Hensley LE, Meyer H, Wright L, Muyembe JJ. 2010. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl. Acad. Sci. U. S. A. 107: 16262-16267.
8. Trindade GS, Emerson GL, Carroll DS, Kroon EG, Damon IK. 2007. Brazilian vaccinia viruses and their origins. Emerg. Infect. Dis. 13:965-972.
9. Bray M, Wright ME. 2003. Progressive vaccinia. Clin. Infect. Dis. 36:766-774.
10. Mayr A. 2003. Smallpox vaccination and bioterrorism with pox viruses. Comp. Immunol. Microbiol. Infect. Dis. 26:423-430.
11. Metzger W, Mordmueller BG. 2007. Vaccines for preventing smallpox. Cochrane Database Syst. Rev. 2007:CD004913.
12. Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, Liu J, Gardner B, Downing G, Blum PS, Kemp T, Nichols R, Weltzin R. 2004. Acam2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain): a second-generation smallpox vaccine for biological defense. Int. J. Infect. Dis. 8:S31-S44.
13. Greenberg RN, Kennedy JS. 2008. Acam2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin. Invest. Drugs 17: 555-564.
14. Kemper AR, Davis MM, Freed GL. 2002. Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract. 5:84-90.
15. Kennedy JS, Greenberg RN. 2009. Imvamune: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev. Vaccines 8:13-24.
16. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ, Jackson DL, Kulesh DA, Martinez MJ, Miller DM, Mucker EM, Shamblin JD, Zwiers SH, Huggins JW, Jahrling PB, Moss B. 2004. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428:182-185.
17. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. 1974. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Deutsch. Med. Wochenschr. 99: 2386-2392. (In German.)
18. Mayr A, Stickl H, Muller HK, Danner K, Singer H. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defense mechanism. Zentralbl. Bakteriol. B 167:375-390. (In German.)
19. FDA. 2002. New drug and biologics and drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed. Regist. 67:37988-37998.
20. Zaucha GM, Jahrling PB, Geisbert TW, Swearengen JR, Hensley L. 2001. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81:1581-1600.
21. Cann JA, Jahrling PB, Hensley LE, Wahl-Jensen V. 2012. Comparative pathology of smallpox and monkeypox in man and macaques. J. Comp. Pathol. [Epub ahead of print.]
22. Druett HA. 1969. A mobile form of the Henderson apparatus. J. Hyg. (Lond.) 67:437-448.
23. Gilles HJ. 1974. Calculation of the index of acute toxicity by the method of linear regression. Comparison with the method of "Karber and Behrens." Eur. J. Toxicol. Environ. Hyg. 7:77-84.
24. Jezek Z, Nakano JH, Arita I, Mutombo M, Szczeniowski M, Dunn C. 1987. Serological survey for human monkeypox infections in a selected population in Zaire. J. Trop. Med. Hyg. 90:31-38.
25. Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, Karem K, Damon IK, Byrd CM, Bolken TC, Jordan Hruby RD. 2009. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53:2620-2625.
26. Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, Johnson W, Chapman J, Twenhafel N, Tyavanagimatt S, Amantana A, Chinsangaram J, Hruby DE, Huggins J. 2009. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53:1817-1822.
27. Shao L, Huang D, Wei H, Wang RC, Chen CY, Shen L, Zhang W, Jin J, Chen ZW. 2009. Expansion, reexpansion, and recall-like expansion of Vγ2V δ2 T cells in smallpox vaccination and monkeypox virus infection. J. Virol. 83:11959-11965.
28. Keasey S, Pugh C, Tikhonov A, Chen G, Schweitzer B, Nalca A, Ulrich RG. 2010. Proteomic basis of the antibody response to monkeypox virus infection examined in cynomolgus macaques and a comparison to human smallpox vaccination. PLoS One 5:e15547. doi:10.1371/journal.pone.0015547.
29. Zielinski RJ, Smedley JV, Perera PY, Silvera PM, Waldmann TA, Capala J, Perera LP. 2010. Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long-term protection against a lethal monkeypox challenge in cynomolgus monkeys. Vaccine 28:7081-7091.
30. Estep RD, Messaoudi I, O'Connor MA, Li H, Sprague J, Barron A, Engelmann AF, Yen B, Powers MF, Jones JM, Robinson BA, Orzechowska BU, Manoharan M, Legasse A, Planer S, Wilk J, Axthelm Wong MKSW. 2011. Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection. J. Virol. 85: 9527-9542.
31. Hirao LA, Draghia-Akli R, Prigge JT, Yang M, Satishchandran A, Wu L, Hammarlund E, Khan AS, Babas T, Rhodes L, Silvera P, Slifka M, Sardesai NY, Weiner DB. 2011. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J. Infect. Dis. 203: 95-102.
32. Golden JW, Josleyn M, Mucker EM, Hung CF, Loudon PT, Wu TC, Hooper JW. 2012. Side-by-side comparison of gene-based smallpox vaccine with MVA in nonhuman primates. PLoS One 7:e42353. doi:10.1371/journal.pone.0042353.
33. Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FH, Niesters HG, van Doornum G, van der Zeijst BA, Mateo L, Chaplin PJ, Osterhaus AD. 2005. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79:7845-7851.
34. Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ, Davis HL, Eisenberg RJ, Cohen GH, Isaacs SN. 2010. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine 28:6627-6636.
35. Denzler KL, Babas T, Rippeon A, Huynh T, Fukushima N, Rhodes L, Silvera PM, Jacobs BL. 2011. Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques. Vaccine 29:9684-9690.
36. Nalca A, Livingston VA, Garza NL, Zumbrun EE, Frick OM, Chapman JL, Hartings JM. 2010. Experimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus. PLoS One 5:12880. doi:10.1371/journal.pone.0012880.
37. Anonymous. 2010. FDA fast track status for Imvamune. Hum. Vaccin. 6:368-372.
38. Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, Yan LK, Chaplin P, Vollmar J, Chaitman BR. 2007. Clinical and immunologic responses to multiple doses of Imvamune (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 25:8562-8573.
39. Garza NL, Hatkin JM, Livingston V, Nichols DK, Chaplin PJ, Volkmann A, Fisher D, Nalca A. 2009. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/Imvamune against aerosolized rabbitpox virus in a rabbit model. Vaccine 27:5496-5504.
40. Keckler MS, Carroll DS, Gallardo-Romero NF, Lash RR, Salzer JS, Weiss SL, Patel N, Clemmons CJ, Smith SK, Hutson CL, Karem Damon KLIK. 2011. Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high-and low-dose monkeypox virus challenges. J. Virol. 85:7683-7698.
41. Barnewall RE, Fisher DA, Robertson AB, Vales PA, Knostman KA, Bigger JE. 2012. Inhalational monkeypox virus infection in cynomolgus macaques. Front. Cell Infect. Microbiol. 2:117.
42. Goff AJ, Chapman J, Foster C, Wlazlowski C, Shamblin J, Lin K, Kreiselmeier N, Mucker E, Paragas J, Lawler J, Hensley L. 2011. A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. J. Virol. 85:4898-4909.
43. Hutin YJ, Williams RJ, Malfait P, Pebody R, Loparev VN, Ropp SL, Rodriguez M, Knight JC, Tshioko FK, Khan AS, Szczeniowski MV, Esposito JJ. 2001. 1996. Outbreak of human monkeypox, Democratic Republic of Congo, to 1997. Emerg. Infect. Dis. 7:434-438.
44. Meyer H, Perrichot M, Stemmler M, Emmerich P, Schmitz H, Varaine F, Shungu R, Tshioko F, Formenty P. 2002. 2001. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo. J. Clin. Microbiol. 40:2919-2921.
45. Reynolds MG, Damon IK. 2012. Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol. 20:80-87.
46. Rimoin AW, Graham BS. 2011. Whither monkeypox vaccination. Vaccine 29:D60-D64